Advanced prostate cancer: Systemic radiopharmaceutical therapy of metastatic prostate cancer with rhenium-186 hydroxyethylidene diphosphonate

Oncology Research and Treatment

Volumn 20, Issue 4, 1997, Pages 316-319

  Schoeneich, G ^a   Palmedo, H ^b   Heimbach, D ^a   Biersack, H J ^b   Midiera, S C ^a  

^a Klin und Poliklin F Urologie   (Germany)

^b UNIVERSITY OF BONN   (Germany)

Author keywords

Advanced prostate cancer; Pain relief; Painful multiloculated bone metastases; Quality of life; Radionuclide therapy; Rhenium 186 HEDP

Indexed keywords

ETIDRONIC ACID RE 186;

ADVANCED CANCER; ARTICLE; BLOOD TOXICITY; BONE MARROW TOXICITY; BONE METASTASIS; CANCER PAIN; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; HUMAN; PAIN ASSESSMENT; PROSTATE CANCER; QUALITY OF LIFE;

EID: 0030808605     PISSN: 22965270     EISSN: None     Source Type: Journal    
DOI: 10.1159/000218962     Document Type: Article

References (26)

1. Epstein LM, Stewart BH, Antunez AR: Half and total body radiation for carcinoma of the prostate. J Urol 1979:122:330-332.
2. Keen CW: Half body radiotherapy in the management of metastatic carcinoma of the prostate. J Urol 1980;123:713-716.
3. Kuban DA, Delbridge T, El-Mahdi AM: Half body irradiation for treatment of widely metastatic adenocarcinoma of the prostate. J Urol 1989;141:572-575.
4. Rowling CG, Bullmore JA, Smith PJB: Half body irradiation in the treatment of metastatic prostatic carcinoma. Br J Urol 1981;53:628-831.
5. De Klerk JMH, Zonnenberg BA, van het Schip AD. van Dijk A. Han SH. Quirij-nen JMSP, Blijham GH, van Rijk PP: Dose escalation study of rhenium-186 HEDP in patients with metastatic prostate cancer. Eur J Nucl Med 1994; 21:1114-1120.
6. De Klerk JMH, van Dijk A, van het Schip AD, Zonnenberg BA, van Rijk PP: Pharmacokinetics of rhenium-186 after administration of rhenium-186 HEDP to patients with bone métastasés. J Nucl Med 1992:33:646-651.
7. Rockville M: Clinical Practice Guideline Number 9 - Management of Cancer Pain. US Department of Health and Human Services. 1994.
8. Robinson RG, Preston DF, Baxter KG: Clinical experience with strontium-89 in prostate and breast cancer patients Semin Oncol 1993:20:44-48.
9. Robinson RG: Systemic radioisotopic therapy of primary and metastatic bone cancer. J Nucl Med 1990;31:1326-1327.
10. Reddy EK, Robinson RG, Mansfield CM: Strontium-89 for palliation of bone métastasés. J Natl Med Assoc 1986:78:27-32.
11. Denis L: Prostate cancer - primary hormonal treatment. Cancer 1993;71: 1050-1058.
12. Firusian N, Mellin P. Schmidt CG: Results of strontium-89 therapy in patients with carcinoma to the prostate and incurable pain from bone métastasés: A preliminary report. J Urol 1976;116:764-768.
13. !WSr-Strontiumchlorid bei 200 Patienten mit Skelettmctastasen eines Prostatakarzinoms. Nuklearmedizin 1992;31:48-52.
14. Laing AH, Ackery DM. Bayly RJ. Buchanan RB, Lewington VJ, McEwan A JB. Macleod PM. Zivanovic MA: Strontium-89 cloride for pain palliation in prostate skeletal malignancy. Br J Urol 1991;64:816-822.
15. McEwan AJB, Amyotte GA, McGowan DC, MacGillivary JA, Porter AT: A retrospective analysis of the cost effectiveness of treatment with Metastron in patients with prostate cancer metastatic to bone. Eur Urol 1994:26 (suppl):26-31.
16. Muller St, Rembrink K, Reiners Ch: Die nuklearmcdizinische Schmerztherapie beim ossär metastasierten Prostatakarzinom. Urologe A 1993:32:121-127.
17. Porter AT, McEwan AJB, Powe JE. Reid RH, McGowan DC, Lukka H, Sathyanarayana JR, Yakemchuk VN, Thomas GM. Erlich LE, Crook J. Guleuchyn KY, Hong KE, Wesolowski C. Yardley J: Results of a randomized phase III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer. Int J Radiat Oncol Bio Phys 1993:25:805-813.
18. Porter AT: Strontium-89 (Metastron) in the treatment of prostate cancer metastatic to bone. Eur Urol 1994:26 (suppl):20-25.
19. Robinson RG, Preston DF, Schiefelbein M, Baxten KG: Strontium-89 therapy for palliation of pain due to osseous métastasés. JAMA 1995;274:420-429.
20. Blake GM, Zivanovic MA, McEwan AJ, Ackery DM. Sr-89 therapy: Strontium kinetics in disseminated carcinoma of the prostate. Eur J Nuc Med 1986:12: 447-454.
21. Eisenhut M: Preparation of Re-186 perrhenate for nuclear medical purpose. Int J Appl Radiat Isot 1982;33:99-103.
22. Maxon HR, Schroder LE, Thomas SR: Re-186 (Sn) HEDP for treatment of painful osseous métastasés: Initial clinical experience in 20 patients with hormone-resistant prostate cancer. Radiology 1990;176:155-159.
23. Maxon HR, Schroder LE, Hertzberg VS: Rhenium-186 HEDP for treatment of painful osseous métastasés, results of a double-blind cross-over comparrison with placebo. J Nucl Med 1991:32:1877-1881.
24. Maxon HR, Thomas SR, Hertzberg VS, Schroder LE, Englaro EE, Samaratunga R, Scher HI, Molton JS, Deutsch EA, Deutsch KF. Scheider HJ, Williams CC. Erhardt GJ: Rhenium-186 hydroxyethylidene diphosphonate for treatment of painful osseous métastasés. Semin Nucl Med 1992:22:33-40.
25. De Klerk JMH, van het Schip AD, Zonnenberg BA: Evaluation of thrombocytopenia in patients treated with rhenium-186 HEDP: Guidelines for individual dosage recommendation. J Nucl Med 1994:35:1423-1428.
26. Zonnenberg BA, de Klerk HJM, van Rijk PP: Re-186 HEDP for treatment of painful bone métastasés in patients with metastatic prostate or breast cancer. J Nucl Med 1991:32:1082-1091.